{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:54:41Z","timestamp":1793386481681,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2013,6,19]],"date-time":"2013-06-19T00:00:00Z","timestamp":1371600000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1007\/s00702-013-1048-3","type":"journal-article","created":{"date-parts":[[2013,6,18]],"date-time":"2013-06-18T05:44:52Z","timestamp":1371534292000},"page":"1699-1707","source":"Crossref","is-referenced-by-count":62,"title":["A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin\u00ae) in cervical dystonia"],"prefix":"10.1007","volume":"120","author":[{"given":"Virgilio Gerald H.","family":"Evidente","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert H.","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"LeDoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Brashear","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Grafe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelika","family":"Hanschmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia L.","family":"Comella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,6,19]]},"reference":[{"key":"1048_CR1","unstructured":"Allergan Inc. (2011) Botox\u00ae US Prescribing Information. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/103000s5232lbl.pdf . Accessed 18 June 2012"},{"key":"1048_CR2","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1212\/01.WNL.0000163767.99354.C3","volume":"64","author":"R Benecke","year":"2005","unstructured":"Benecke R, Jost WH, Kanovsky P, Ruzicka E, Comes G, Grafe S (2005) A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology 64:1949\u20131951","journal-title":"Neurology"},{"key":"1048_CR3","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/mds.22157","volume":"23","author":"MF Brin","year":"2008","unstructured":"Brin MF, Comella CL, Jankovic J, Lai F, Naumann M (2008) Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord 23:1353\u20131360","journal-title":"Mov Disord"},{"key":"1048_CR4","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/mds.870060206","volume":"6","author":"J Chan","year":"1991","unstructured":"Chan J, Brin MF, Fahn S (1991) Idiopathic cervical dystonia: clinical characteristics. Mov Disord 6:119\u2013126","journal-title":"Mov Disord"},{"key":"1048_CR5","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1212\/WNL.42.7.1307","volume":"42","author":"CL Comella","year":"1992","unstructured":"Comella CL, Tanner CM, DeFoor-Hill L, Smith C (1992) Dysphagia after botulinum toxin injections for spasmodic torticollis: clinical and radiologic findings. Neurology 42:1307\u20131310","journal-title":"Neurology"},{"key":"1048_CR6","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1212\/01.wnl.0000183055.81056.5c","volume":"65","author":"CL Comella","year":"2005","unstructured":"Comella CL, Jankovic J, Shannon KM, Tsui J, Swenson M, Leurgans S, Fan W (2005) Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology 65:1423\u20131429","journal-title":"Neurology"},{"key":"1048_CR7","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jns.2011.05.041","volume":"308","author":"CL Comella","year":"2011","unstructured":"Comella CL, Jankovic J, Truong DD, Hanschmann A, Grafe S (2011) Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN\u00ae, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. J Neurol Sci 308:103\u2013109","journal-title":"J Neurol Sci"},{"key":"1048_CR8","first-page":"211","volume-title":"Therapy with botulinum toxin","author":"ES Consky","year":"1994","unstructured":"Consky ES, Lang AE (1994) Therapy with botulinum toxin. Marcel Dekker, Inc., New York, pp 211\u2013237"},{"key":"1048_CR9","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000064953","volume":"48","author":"D Dressler","year":"2002","unstructured":"Dressler D (2002) Clinical features of antibody-induced complete secondary failure of botulinum toxin therapy. Eur Neurol 48:26\u201329","journal-title":"Eur Neurol"},{"key":"1048_CR10","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1468-1331.2011.03559.x","volume":"19","author":"D Dressler","year":"2012","unstructured":"Dressler D (2012) Five-year experience with incobotulinumtoxinA (Xeomin((\u00ae)): the first botulinum toxin drug free of complexing proteins. Eur J Neurol 19:385\u2013389","journal-title":"Eur J Neurol"},{"key":"1048_CR11","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00702-011-0719-1","volume":"119","author":"D Dressler","year":"2011","unstructured":"Dressler D, Mander G, Fink K (2011) Measuring the potency labelling of onabotulinumtoxinA (Botox(\u00ae)) and incobotulinumtoxinA (Xeomin (\u00ae)) in an LD50 assay. J Neural Transm 119:13\u201315","journal-title":"J Neural Transm"},{"key":"1048_CR12","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.toxicon.2009.03.010","volume":"54","author":"J Frevert","year":"2009","unstructured":"Frevert J (2009) Xeomin is free from complexing proteins. Toxicon 54:697\u2013701","journal-title":"Toxicon"},{"key":"1048_CR13","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2165\/11584780-000000000-00000","volume":"10","author":"J Frevert","year":"2010","unstructured":"Frevert J (2010) Content of botulinum neurotoxin in botox\u00ae\/vistabel\u00ae, dysport\u00ae\/azzalure\u00ae, and xeomin\u00ae\/bocouture\u00ae. Drugs R D 10:67\u201373","journal-title":"Drugs R D"},{"key":"1048_CR14","first-page":"325","volume":"4","author":"J Frevert","year":"2010","unstructured":"Frevert J, Dressler D (2010) Complexing proteins in botulinum toxin type A drugs: a help or a hindrance? Biologics 4:325\u2013332","journal-title":"Biologics"},{"key":"1048_CR15","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1006\/exnr.1997.6580","volume":"147","author":"H G\u00f6schel","year":"1997","unstructured":"G\u00f6schel H, Wohlfarth K, Frevert J, Dengler R, Bigalke H (1997) Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies\u2014therapeutic consequences. Exp Neurol 147:96\u2013102","journal-title":"Exp Neurol"},{"key":"1048_CR16","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/mds.870090216","volume":"9","author":"P Greene","year":"1994","unstructured":"Greene P, Fahn S, Diamond B (1994) Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord 9:213\u2013217","journal-title":"Mov Disord"},{"key":"1048_CR17","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1128\/IAI.64.5.1589-1594.1996","volume":"64","author":"K Inoue","year":"1996","unstructured":"Inoue K, Fujinaga Y, Watanabe T, Ohyama T, Takeshi K, Moriishi K, Nakajima H, Inoue K, Oguma K (1996) Molecular composition of Clostridium botulinum type A progenitor toxins. Infect Immun 64:1589\u20131594","journal-title":"Infect Immun"},{"key":"1048_CR18","unstructured":"Ipsen Biopharm, Ltd (2009) Dysport US prescribing information. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/125274s0052lbl.pdf . Accessed 19 June 2012"},{"key":"1048_CR19","unstructured":"Merz Pharmaceuticals GmbH (2011) Xeomin\u00ae US Prescribing Information. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/125360s007lbl.pdf . Accessed 19 June 2012"},{"key":"1048_CR20","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1002\/mds.23254","volume":"25","author":"M Naumann","year":"2010","unstructured":"Naumann M, Carruthers A, Carruthers J, Aurora SK, Zafonte R, Abu-Shakra S, Boodhoo T, Miller-Messana MA, Demos G, James L, Beddingfield F, VanDenburgh A, Chapman MA, Brin MF (2010) Meta-analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX\u00ae) across multiple indications. Mov Disord 25:2211\u20132218","journal-title":"Mov Disord"},{"issue":"Suppl 8","key":"1048_CR21","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1002\/mds.20021","volume":"19","author":"D Sesardic","year":"2004","unstructured":"Sesardic D, Jones RG, Leung T, Alsop T, Tierney R (2004) Detection of antibodies against botulinum toxins. Mov Disord 19(Suppl 8):S85\u2013S91","journal-title":"Mov Disord"},{"key":"1048_CR22","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3111\/13696998.2011.653726","volume":"15","author":"KD Sethi","year":"2012","unstructured":"Sethi KD, Rodriguez R, Olayinka B (2012) Satisfaction with botulinum toxin treatment: a cross-sectional survey of patients with cervical dystonia. J Med Econ 15:419\u2013423","journal-title":"J Med Econ"},{"key":"1048_CR23","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1212\/01.wnl.0000311389.26145.95","volume":"70","author":"DM Simpson","year":"2008","unstructured":"Simpson DM, Blitzer A, Brashear A, Comella C, Dubinsky R, Hallett M, Jankovic J, Karp B, Ludlow CL, Miyasaki JM, Naumann M, So Y (2008) Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 70:1699\u20131706","journal-title":"Neurology"},{"key":"1048_CR24","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/mds.20403","volume":"20","author":"D Truong","year":"2005","unstructured":"Truong D, Duane DD, Jankovic J, Singer C, Seeberger LC, Comella CL, Lew MF, Rodnitzky RL, Danisi FO, Sutton JP, Charles PD, Hauser RA, Sheean GL (2005) Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord 20:783\u2013791","journal-title":"Mov Disord"},{"key":"1048_CR25","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S0885-3924(00)00146-9","volume":"20","author":"J Wissel","year":"2000","unstructured":"Wissel J, M\u00fcller J, Dressnandt J, Heinen F, Naumann M, Topka H, Poewe W (2000) Management of spasticity associated pain with botulinum toxin A. J Pain Symp Manage 20:44\u201349","journal-title":"J Pain Symp Manage"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-013-1048-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00702-013-1048-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-013-1048-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T17:08:04Z","timestamp":1595956084000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00702-013-1048-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,19]]},"references-count":25,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["1048"],"URL":"https:\/\/doi.org\/10.1007\/s00702-013-1048-3","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,19]]}}}